This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): Pemtumomab, yttrium-90-labeled HMFG1 murine monoclonal antibody
Description: R1549 is an yttrium-90 labelled mouse monoclonal antibody (MAB) directed at MUC-1, a mucin found on various cancer cells.
Deal Structure: R1549 is being co-developed by Antisoma and Roche. Roche has worldwide marketing rights under an agreement between the companies signed in November 2002.
In September 2003, Antisoma acquired royalty rights to R1549 from Cytogen.
Partners: Antisoma plc
Additional information available to subscribers only: